| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 462 | 2023 | 21025 | 12.430 |
Why?
|
| Receptor, erbB-2 | 146 | 2023 | 2554 | 9.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 189 | 2023 | 11712 | 6.830 |
Why?
|
| Paclitaxel | 69 | 2023 | 1736 | 4.810 |
Why?
|
| Aromatase Inhibitors | 39 | 2021 | 511 | 4.310 |
Why?
|
| Receptors, Estrogen | 77 | 2022 | 2210 | 3.800 |
Why?
|
| Chemotherapy, Adjuvant | 120 | 2022 | 3529 | 3.760 |
Why?
|
| Antineoplastic Agents, Hormonal | 49 | 2022 | 1529 | 3.160 |
Why?
|
| Tamoxifen | 43 | 2022 | 963 | 2.920 |
Why?
|
| Quinazolines | 27 | 2021 | 1363 | 2.480 |
Why?
|
| Antineoplastic Agents | 87 | 2022 | 13630 | 2.430 |
Why?
|
| Neoadjuvant Therapy | 45 | 2022 | 2821 | 2.080 |
Why?
|
| Receptors, Progesterone | 41 | 2022 | 1130 | 2.040 |
Why?
|
| Breast Neoplasms, Male | 9 | 2023 | 221 | 1.800 |
Why?
|
| Carcinoma, Ductal, Breast | 15 | 2022 | 1096 | 1.620 |
Why?
|
| Neoplasm Recurrence, Local | 54 | 2023 | 9276 | 1.620 |
Why?
|
| Brain Neoplasms | 30 | 2023 | 8986 | 1.610 |
Why?
|
| Medical Oncology | 18 | 2021 | 2313 | 1.550 |
Why?
|
| Nitriles | 20 | 2021 | 956 | 1.480 |
Why?
|
| Female | 497 | 2023 | 391270 | 1.480 |
Why?
|
| Triazoles | 19 | 2017 | 904 | 1.470 |
Why?
|
| Disease-Free Survival | 69 | 2022 | 6828 | 1.470 |
Why?
|
| Neoplasm Staging | 97 | 2022 | 11152 | 1.450 |
Why?
|
| Vinblastine | 18 | 2013 | 487 | 1.400 |
Why?
|
| Pyridines | 14 | 2022 | 2879 | 1.240 |
Why?
|
| Neoplasm Metastasis | 63 | 2021 | 4902 | 1.240 |
Why?
|
| Cyclophosphamide | 42 | 2020 | 2221 | 1.180 |
Why?
|
| Humans | 558 | 2023 | 760621 | 1.160 |
Why?
|
| Mastectomy, Segmental | 22 | 2021 | 972 | 1.150 |
Why?
|
| Carboplatin | 11 | 2022 | 788 | 1.140 |
Why?
|
| Fluorouracil | 30 | 2019 | 1631 | 1.140 |
Why?
|
| Doxorubicin | 42 | 2020 | 2209 | 1.120 |
Why?
|
| Middle Aged | 286 | 2023 | 220352 | 1.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 13 | 2016 | 626 | 1.110 |
Why?
|
| Postmenopause | 24 | 2022 | 2509 | 1.090 |
Why?
|
| Clinical Trials as Topic | 31 | 2020 | 8056 | 1.060 |
Why?
|
| Deoxycytidine | 19 | 2014 | 873 | 1.050 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 12 | 2015 | 936 | 1.050 |
Why?
|
| Aged | 252 | 2022 | 169152 | 1.030 |
Why?
|
| Antibodies, Monoclonal | 31 | 2018 | 9185 | 1.030 |
Why?
|
| Oxazoles | 4 | 2021 | 199 | 1.000 |
Why?
|
| Epothilones | 5 | 2021 | 42 | 0.960 |
Why?
|
| Protein Kinase Inhibitors | 19 | 2022 | 5643 | 0.930 |
Why?
|
| Adult | 249 | 2022 | 219994 | 0.920 |
Why?
|
| Treatment Outcome | 124 | 2023 | 65017 | 0.920 |
Why?
|
| Consensus Development Conferences as Topic | 4 | 2019 | 169 | 0.900 |
Why?
|
| Maytansine | 6 | 2021 | 86 | 0.900 |
Why?
|
| Mammography | 12 | 2021 | 2427 | 0.890 |
Why?
|
| Survival Analysis | 41 | 2022 | 10182 | 0.890 |
Why?
|
| Carcinoma, Lobular | 9 | 2022 | 489 | 0.870 |
Why?
|
| Taxoids | 13 | 2022 | 669 | 0.870 |
Why?
|
| Neoplasms, Hormone-Dependent | 9 | 2014 | 412 | 0.850 |
Why?
|
| Mastectomy | 33 | 2022 | 1832 | 0.850 |
Why?
|
| Albumins | 8 | 2021 | 575 | 0.830 |
Why?
|
| Survivors | 20 | 2021 | 2375 | 0.820 |
Why?
|
| Cisplatin | 13 | 2021 | 1644 | 0.800 |
Why?
|
| Genes, BRCA1 | 18 | 2018 | 765 | 0.780 |
Why?
|
| Quality of Life | 40 | 2022 | 13308 | 0.770 |
Why?
|
| Piperazines | 12 | 2022 | 2525 | 0.700 |
Why?
|
| Drug Resistance, Neoplasm | 26 | 2022 | 5253 | 0.700 |
Why?
|
| Anilides | 3 | 2019 | 409 | 0.690 |
Why?
|
| Antimetabolites, Antineoplastic | 8 | 2019 | 640 | 0.680 |
Why?
|
| Aged, 80 and over | 103 | 2021 | 58995 | 0.680 |
Why?
|
| Prognosis | 65 | 2022 | 29658 | 0.670 |
Why?
|
| Antibiotics, Antineoplastic | 8 | 2021 | 675 | 0.670 |
Why?
|
| Anthracyclines | 12 | 2021 | 283 | 0.660 |
Why?
|
| Disclosure | 4 | 2009 | 738 | 0.660 |
Why?
|
| Drug Administration Schedule | 36 | 2020 | 4899 | 0.640 |
Why?
|
| Kaplan-Meier Estimate | 32 | 2021 | 6544 | 0.630 |
Why?
|
| Interdisciplinary Communication | 5 | 2021 | 934 | 0.630 |
Why?
|
| Trinitrotoluene | 1 | 2018 | 6 | 0.630 |
Why?
|
| Survival Rate | 43 | 2021 | 12808 | 0.620 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 8 | 2016 | 629 | 0.620 |
Why?
|
| Aminopyridines | 8 | 2022 | 564 | 0.620 |
Why?
|
| Exercise Therapy | 4 | 2019 | 919 | 0.610 |
Why?
|
| Lymphatic Metastasis | 27 | 2021 | 2943 | 0.590 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 8 | 2021 | 895 | 0.590 |
Why?
|
| Platinum Compounds | 3 | 2015 | 95 | 0.570 |
Why?
|
| Fertility | 3 | 2008 | 773 | 0.560 |
Why?
|
| Androstadienes | 7 | 2020 | 348 | 0.550 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2020 | 2418 | 0.550 |
Why?
|
| Phthalazines | 6 | 2022 | 383 | 0.540 |
Why?
|
| Exercise | 9 | 2021 | 5787 | 0.540 |
Why?
|
| Combined Modality Therapy | 34 | 2021 | 8552 | 0.530 |
Why?
|
| Breast | 14 | 2023 | 1963 | 0.530 |
Why?
|
| SEER Program | 20 | 2022 | 1530 | 0.530 |
Why?
|
| Enzyme Inhibitors | 9 | 2010 | 3726 | 0.520 |
Why?
|
| Quinolines | 7 | 2022 | 759 | 0.520 |
Why?
|
| Genes, erbB-2 | 7 | 2011 | 162 | 0.520 |
Why?
|
| Neutropenia | 8 | 2022 | 884 | 0.500 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 1088 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 14 | 2019 | 7475 | 0.480 |
Why?
|
| Physical Fitness | 3 | 2016 | 732 | 0.460 |
Why?
|
| Menopause | 7 | 2009 | 1640 | 0.460 |
Why?
|
| Mutation | 37 | 2022 | 29932 | 0.450 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2019 | 708 | 0.450 |
Why?
|
| Neoplasms, Second Primary | 5 | 2016 | 1056 | 0.450 |
Why?
|
| Premenopause | 11 | 2018 | 1038 | 0.450 |
Why?
|
| Body Mass Index | 7 | 2021 | 12914 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 24 | 2018 | 10344 | 0.430 |
Why?
|
| Follow-Up Studies | 50 | 2021 | 39261 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2021 | 8515 | 0.430 |
Why?
|
| Clinical Trials, Phase III as Topic | 7 | 2013 | 861 | 0.430 |
Why?
|
| Filgrastim | 8 | 2020 | 132 | 0.420 |
Why?
|
| Ovarian Neoplasms | 14 | 2020 | 4878 | 0.420 |
Why?
|
| Adaptation, Psychological | 7 | 2014 | 2628 | 0.420 |
Why?
|
| Age Factors | 34 | 2019 | 18416 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 27 | 2019 | 10827 | 0.410 |
Why?
|
| Estrogen Receptor Modulators | 5 | 2010 | 58 | 0.400 |
Why?
|
| Genetic Testing | 13 | 2021 | 3531 | 0.400 |
Why?
|
| Colony-Stimulating Factors | 1 | 2012 | 218 | 0.400 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2013 | 916 | 0.400 |
Why?
|
| Immunity | 1 | 2018 | 998 | 0.400 |
Why?
|
| Lymph Node Excision | 9 | 2017 | 1303 | 0.390 |
Why?
|
| Body Weight | 2 | 2021 | 4611 | 0.390 |
Why?
|
| Estrogen Receptor alpha | 4 | 2020 | 580 | 0.390 |
Why?
|
| Attitude of Health Personnel | 7 | 2020 | 3865 | 0.380 |
Why?
|
| Radiotherapy | 12 | 2017 | 1504 | 0.380 |
Why?
|
| Population Surveillance | 4 | 2017 | 2608 | 0.370 |
Why?
|
| Genes, BRCA2 | 8 | 2018 | 603 | 0.370 |
Why?
|
| Disease Progression | 25 | 2021 | 13502 | 0.360 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2015 | 245 | 0.360 |
Why?
|
| Research Subjects | 4 | 2007 | 249 | 0.360 |
Why?
|
| Estrogen Antagonists | 4 | 2022 | 151 | 0.360 |
Why?
|
| Decision Making | 8 | 2017 | 3925 | 0.360 |
Why?
|
| Amenorrhea | 3 | 2021 | 480 | 0.350 |
Why?
|
| Palliative Care | 5 | 2020 | 3607 | 0.350 |
Why?
|
| Radiotherapy, Adjuvant | 15 | 2019 | 1791 | 0.350 |
Why?
|
| Informed Consent | 4 | 2011 | 1005 | 0.350 |
Why?
|
| Ketones | 2 | 2021 | 183 | 0.350 |
Why?
|
| Proportional Hazards Models | 23 | 2023 | 12531 | 0.340 |
Why?
|
| Furans | 2 | 2021 | 199 | 0.340 |
Why?
|
| United States | 58 | 2021 | 72461 | 0.340 |
Why?
|
| Neoplasms | 27 | 2021 | 22072 | 0.340 |
Why?
|
| Life Style | 3 | 2013 | 3896 | 0.330 |
Why?
|
| Preoperative Care | 6 | 2019 | 2256 | 0.330 |
Why?
|
| Purines | 4 | 2022 | 605 | 0.330 |
Why?
|
| Societies, Medical | 10 | 2020 | 3905 | 0.330 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 1392 | 0.320 |
Why?
|
| Endpoint Determination | 3 | 2021 | 597 | 0.320 |
Why?
|
| Physical Endurance | 2 | 2009 | 363 | 0.320 |
Why?
|
| Bone Marrow Transplantation | 4 | 2005 | 2693 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase 4 | 5 | 2022 | 556 | 0.320 |
Why?
|
| Thiazoles | 6 | 2022 | 1511 | 0.320 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2021 | 938 | 0.310 |
Why?
|
| Neoplasm Proteins | 6 | 2010 | 3610 | 0.300 |
Why?
|
| Neoplasm Invasiveness | 11 | 2019 | 3618 | 0.290 |
Why?
|
| Breast Diseases | 2 | 2007 | 443 | 0.290 |
Why?
|
| Biopsy | 9 | 2022 | 6771 | 0.290 |
Why?
|
| Maximum Tolerated Dose | 9 | 2021 | 877 | 0.290 |
Why?
|
| Molecular Targeted Therapy | 9 | 2018 | 2803 | 0.290 |
Why?
|
| Cohort Studies | 36 | 2023 | 41335 | 0.290 |
Why?
|
| Healthcare Disparities | 7 | 2015 | 3388 | 0.280 |
Why?
|
| Sentinel Lymph Node Biopsy | 8 | 2017 | 733 | 0.280 |
Why?
|
| Time Factors | 33 | 2022 | 40165 | 0.280 |
Why?
|
| Estrogens | 2 | 2021 | 1520 | 0.280 |
Why?
|
| Ovary | 2 | 2016 | 958 | 0.280 |
Why?
|
| Medication Adherence | 4 | 2014 | 2165 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2020 | 3986 | 0.270 |
Why?
|
| Morpholines | 3 | 2020 | 583 | 0.270 |
Why?
|
| Prospective Studies | 39 | 2023 | 54303 | 0.270 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2022 | 3602 | 0.270 |
Why?
|
| Genomics | 7 | 2021 | 5794 | 0.270 |
Why?
|
| Patient Participation | 7 | 2015 | 1439 | 0.270 |
Why?
|
| Repressor Proteins | 2 | 2017 | 2981 | 0.270 |
Why?
|
| Polyethylene Glycols | 6 | 2020 | 1189 | 0.270 |
Why?
|
| Neoplasm, Residual | 5 | 2022 | 1007 | 0.270 |
Why?
|
| Carcinoma in Situ | 2 | 2010 | 796 | 0.260 |
Why?
|
| Health Care Reform | 2 | 2012 | 1245 | 0.260 |
Why?
|
| Young Adult | 35 | 2021 | 58741 | 0.260 |
Why?
|
| Biomedical Research | 7 | 2020 | 3426 | 0.260 |
Why?
|
| Risk Factors | 43 | 2022 | 74359 | 0.260 |
Why?
|
| Carcinoma | 4 | 2015 | 2331 | 0.260 |
Why?
|
| BRCA1 Protein | 6 | 2022 | 1147 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase 6 | 3 | 2018 | 346 | 0.260 |
Why?
|
| Lymph Nodes | 8 | 2019 | 3486 | 0.250 |
Why?
|
| Patient Care Team | 8 | 2013 | 2511 | 0.250 |
Why?
|
| Referral and Consultation | 4 | 2020 | 3598 | 0.250 |
Why?
|
| Carbazoles | 1 | 2006 | 220 | 0.240 |
Why?
|
| Ki-67 Antigen | 5 | 2021 | 631 | 0.240 |
Why?
|
| BRCA2 Protein | 5 | 2020 | 798 | 0.240 |
Why?
|
| Double-Blind Method | 11 | 2020 | 12427 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2021 | 17790 | 0.230 |
Why?
|
| Tumor Microenvironment | 6 | 2021 | 3844 | 0.230 |
Why?
|
| Infusions, Intravenous | 9 | 2020 | 2234 | 0.230 |
Why?
|
| Logistic Models | 17 | 2021 | 13314 | 0.230 |
Why?
|
| Remission Induction | 6 | 2016 | 2392 | 0.220 |
Why?
|
| Muscle Strength | 1 | 2008 | 619 | 0.220 |
Why?
|
| Erythropoietin | 2 | 2005 | 720 | 0.220 |
Why?
|
| Patient Compliance | 4 | 2012 | 2688 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2014 | 1403 | 0.220 |
Why?
|
| Administration, Oral | 11 | 2019 | 4035 | 0.220 |
Why?
|
| Arthralgia | 1 | 2007 | 461 | 0.220 |
Why?
|
| Loss of Heterozygosity | 3 | 2016 | 659 | 0.220 |
Why?
|
| Patient Selection | 11 | 2020 | 4283 | 0.220 |
Why?
|
| Chromans | 1 | 2003 | 117 | 0.220 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 1115 | 0.210 |
Why?
|
| Cytarabine | 1 | 2005 | 696 | 0.210 |
Why?
|
| Benzamides | 4 | 2020 | 1369 | 0.210 |
Why?
|
| Survival | 2 | 2003 | 161 | 0.210 |
Why?
|
| Insurance, Health | 2 | 2012 | 2501 | 0.210 |
Why?
|
| Gene Expression Profiling | 14 | 2021 | 9411 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2022 | 2864 | 0.210 |
Why?
|
| Patient Satisfaction | 6 | 2013 | 3448 | 0.210 |
Why?
|
| Anxiety | 8 | 2015 | 4538 | 0.210 |
Why?
|
| DNA Copy Number Variations | 5 | 2021 | 2013 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2020 | 3484 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2016 | 1394 | 0.200 |
Why?
|
| Sarcoidosis | 1 | 2007 | 520 | 0.200 |
Why?
|
| Ethics, Clinical | 1 | 2002 | 101 | 0.200 |
Why?
|
| Socioeconomic Factors | 9 | 2020 | 7806 | 0.200 |
Why?
|
| Estradiol | 4 | 2019 | 1932 | 0.190 |
Why?
|
| Anemia | 3 | 2007 | 1511 | 0.190 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2020 | 256 | 0.190 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 886 | 0.190 |
Why?
|
| Markov Chains | 7 | 2011 | 968 | 0.190 |
Why?
|
| Continuity of Patient Care | 2 | 2005 | 1066 | 0.190 |
Why?
|
| Weight Gain | 6 | 2010 | 2347 | 0.190 |
Why?
|
| Obesity | 2 | 2021 | 12922 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2009 | 1613 | 0.190 |
Why?
|
| Methotrexate | 10 | 2019 | 1719 | 0.190 |
Why?
|
| Attitude to Health | 4 | 2005 | 2029 | 0.190 |
Why?
|
| Germ-Line Mutation | 3 | 2021 | 1841 | 0.190 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2020 | 17 | 0.180 |
Why?
|
| Perception | 4 | 2013 | 1195 | 0.180 |
Why?
|
| Spouses | 1 | 2003 | 279 | 0.180 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2013 | 107 | 0.180 |
Why?
|
| Risk Assessment | 20 | 2021 | 24123 | 0.180 |
Why?
|
| Consensus | 3 | 2020 | 3113 | 0.180 |
Why?
|
| Research Design | 5 | 2021 | 6180 | 0.180 |
Why?
|
| Predictive Value of Tests | 15 | 2021 | 15289 | 0.180 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 6315 | 0.180 |
Why?
|
| Risk | 7 | 2020 | 9631 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2021 | 1999 | 0.180 |
Why?
|
| Diarrhea | 3 | 2019 | 1319 | 0.180 |
Why?
|
| Patient Care Planning | 1 | 2005 | 908 | 0.170 |
Why?
|
| Patient Advocacy | 2 | 2015 | 358 | 0.170 |
Why?
|
| Receptors, Steroid | 3 | 2020 | 154 | 0.170 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 465 | 0.170 |
Why?
|
| Phenylthiohydantoin | 2 | 2020 | 204 | 0.170 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2003 | 563 | 0.170 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2019 | 146 | 0.170 |
Why?
|
| Fatigue | 6 | 2015 | 1544 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2015 | 629 | 0.170 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2014 | 487 | 0.170 |
Why?
|
| Registries | 6 | 2023 | 8469 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2020 | 120 | 0.170 |
Why?
|
| Multivariate Analysis | 14 | 2019 | 12159 | 0.170 |
Why?
|
| Recurrence | 6 | 2019 | 8482 | 0.170 |
Why?
|
| Antigens, CD20 | 2 | 2011 | 201 | 0.170 |
Why?
|
| Drug Delivery Systems | 2 | 2008 | 2221 | 0.160 |
Why?
|
| Transplantation, Autologous | 3 | 2005 | 2116 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 211 | 0.160 |
Why?
|
| Recombinant Proteins | 9 | 2010 | 6538 | 0.160 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 279 | 0.160 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 1428 | 0.160 |
Why?
|
| Life Expectancy | 3 | 2021 | 1248 | 0.160 |
Why?
|
| Male | 49 | 2023 | 359744 | 0.160 |
Why?
|
| Truth Disclosure | 1 | 2003 | 432 | 0.160 |
Why?
|
| Tegafur | 1 | 1998 | 39 | 0.160 |
Why?
|
| Radiosurgery | 2 | 2021 | 1343 | 0.160 |
Why?
|
| Pilot Projects | 11 | 2019 | 8555 | 0.160 |
Why?
|
| Complementary Therapies | 1 | 2002 | 486 | 0.150 |
Why?
|
| Cell Proliferation | 8 | 2021 | 10446 | 0.150 |
Why?
|
| Phenotype | 1 | 2016 | 16546 | 0.150 |
Why?
|
| Sensory Receptor Cells | 2 | 2014 | 509 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 4 | 2013 | 1722 | 0.150 |
Why?
|
| Indoles | 1 | 2006 | 1829 | 0.150 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 542 | 0.150 |
Why?
|
| Amifostine | 3 | 2003 | 40 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2020 | 384 | 0.150 |
Why?
|
| Endometrial Neoplasms | 1 | 2007 | 1357 | 0.150 |
Why?
|
| Patient Education as Topic | 7 | 2012 | 2315 | 0.150 |
Why?
|
| Pathology, Surgical | 2 | 2009 | 151 | 0.150 |
Why?
|
| Axilla | 7 | 2017 | 626 | 0.150 |
Why?
|
| Poisson Distribution | 1 | 2019 | 507 | 0.150 |
Why?
|
| Salvage Therapy | 5 | 2016 | 1268 | 0.150 |
Why?
|
| Body Image | 2 | 2012 | 635 | 0.140 |
Why?
|
| Meningeal Neoplasms | 2 | 2004 | 1249 | 0.140 |
Why?
|
| Retrospective Studies | 33 | 2023 | 80372 | 0.140 |
Why?
|
| Uracil | 1 | 1998 | 207 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 2049 | 0.140 |
Why?
|
| Integrative Medicine | 1 | 2018 | 87 | 0.140 |
Why?
|
| Quality of Health Care | 3 | 2009 | 4360 | 0.140 |
Why?
|
| Epirubicin | 3 | 2013 | 83 | 0.140 |
Why?
|
| Research Support as Topic | 3 | 2012 | 699 | 0.140 |
Why?
|
| Leukemia, Myeloid | 1 | 2020 | 695 | 0.140 |
Why?
|
| Evidence-Based Medicine | 7 | 2018 | 3696 | 0.140 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 3465 | 0.140 |
Why?
|
| Silicones | 2 | 1996 | 227 | 0.130 |
Why?
|
| Patients | 1 | 2003 | 906 | 0.130 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2011 | 105 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2020 | 495 | 0.130 |
Why?
|
| Basal Metabolism | 1 | 1997 | 161 | 0.130 |
Why?
|
| Camptothecin | 2 | 2023 | 590 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2021 | 2007 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2020 | 2448 | 0.130 |
Why?
|
| Immunohistochemistry | 10 | 2021 | 11071 | 0.130 |
Why?
|
| Cell Line, Tumor | 12 | 2020 | 16939 | 0.130 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 77 | 0.130 |
Why?
|
| Heart Diseases | 5 | 2010 | 2809 | 0.130 |
Why?
|
| Drug Therapy | 1 | 1999 | 504 | 0.130 |
Why?
|
| Communication | 2 | 2008 | 3849 | 0.130 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 734 | 0.130 |
Why?
|
| Cell Cycle Proteins | 4 | 2020 | 3446 | 0.130 |
Why?
|
| Attitude | 1 | 2020 | 777 | 0.130 |
Why?
|
| Hospitals | 1 | 2009 | 3928 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2016 | 567 | 0.130 |
Why?
|
| Focus Groups | 2 | 2000 | 1378 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 801 | 0.130 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 609 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2023 | 949 | 0.120 |
Why?
|
| Pneumocystis carinii | 1 | 2015 | 72 | 0.120 |
Why?
|
| Women's Health | 3 | 2012 | 2056 | 0.120 |
Why?
|
| Adolescent | 19 | 2021 | 87810 | 0.120 |
Why?
|
| Pyrrolidinones | 1 | 2015 | 116 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 3616 | 0.120 |
Why?
|
| Europe | 3 | 2018 | 3441 | 0.120 |
Why?
|
| Research | 3 | 2013 | 1974 | 0.120 |
Why?
|
| Decision Support Techniques | 6 | 2008 | 2001 | 0.120 |
Why?
|
| Opportunistic Infections | 2 | 2015 | 377 | 0.120 |
Why?
|
| Body Height | 1 | 2021 | 1570 | 0.120 |
Why?
|
| Nurses | 1 | 2004 | 2467 | 0.120 |
Why?
|
| Prescription Fees | 1 | 2015 | 151 | 0.120 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 1791 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2018 | 547 | 0.120 |
Why?
|
| Medical History Taking | 2 | 1998 | 773 | 0.110 |
Why?
|
| Reproductive History | 1 | 2015 | 210 | 0.110 |
Why?
|
| Odds Ratio | 9 | 2016 | 9716 | 0.110 |
Why?
|
| Platinum | 3 | 2021 | 223 | 0.110 |
Why?
|
| Receptors, Androgen | 2 | 2018 | 1077 | 0.110 |
Why?
|
| Tretinoin | 1 | 1997 | 519 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 544 | 0.110 |
Why?
|
| Treatment Failure | 4 | 2014 | 2648 | 0.110 |
Why?
|
| Azepines | 1 | 2016 | 330 | 0.110 |
Why?
|
| Transcription Factors | 5 | 2022 | 12103 | 0.110 |
Why?
|
| Endocrine System | 1 | 2014 | 112 | 0.110 |
Why?
|
| Family | 4 | 2002 | 3189 | 0.110 |
Why?
|
| Inflammation | 2 | 2012 | 10756 | 0.110 |
Why?
|
| Insulin | 1 | 2008 | 6597 | 0.110 |
Why?
|
| Hormones | 4 | 2022 | 867 | 0.110 |
Why?
|
| Gene Expression | 2 | 2016 | 7588 | 0.110 |
Why?
|
| Drug Synergism | 3 | 2010 | 1754 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2013 | 558 | 0.110 |
Why?
|
| Multiprotein Complexes | 2 | 2016 | 1120 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 124 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 2640 | 0.110 |
Why?
|
| Telemedicine | 1 | 2010 | 3018 | 0.110 |
Why?
|
| Liposomes | 5 | 2004 | 777 | 0.110 |
Why?
|
| Tumor Burden | 5 | 2019 | 1895 | 0.110 |
Why?
|
| Alleles | 3 | 2018 | 6898 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2014 | 297 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 3775 | 0.100 |
Why?
|
| Self-Help Groups | 1 | 2014 | 189 | 0.100 |
Why?
|
| Chromatin | 3 | 2022 | 2938 | 0.100 |
Why?
|
| Comorbidity | 9 | 2015 | 10551 | 0.100 |
Why?
|
| Portugal | 1 | 2012 | 91 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2016 | 2058 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 3584 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 431 | 0.100 |
Why?
|
| Congresses as Topic | 4 | 2011 | 805 | 0.100 |
Why?
|
| Immunotoxins | 1 | 2012 | 175 | 0.100 |
Why?
|
| Carmustine | 3 | 2005 | 138 | 0.100 |
Why?
|
| DNA Repair | 2 | 2018 | 2039 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2018 | 563 | 0.100 |
Why?
|
| Patient Preference | 2 | 2017 | 922 | 0.100 |
Why?
|
| Delayed Diagnosis | 2 | 2013 | 464 | 0.100 |
Why?
|
| Mass Screening | 4 | 2021 | 5423 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 2 | 2015 | 1484 | 0.100 |
Why?
|
| Standard of Care | 1 | 2015 | 552 | 0.100 |
Why?
|
| Physicians | 3 | 2015 | 4591 | 0.100 |
Why?
|
| Cranial Irradiation | 1 | 2014 | 391 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2014 | 296 | 0.100 |
Why?
|
| Mesna | 2 | 2002 | 62 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2014 | 6360 | 0.090 |
Why?
|
| Razoxane | 2 | 2002 | 43 | 0.090 |
Why?
|
| Societies | 1 | 2012 | 108 | 0.090 |
Why?
|
| Environment Design | 1 | 2013 | 172 | 0.090 |
Why?
|
| Medicare | 9 | 2018 | 6786 | 0.090 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 424 | 0.090 |
Why?
|
| Nausea | 3 | 2013 | 678 | 0.090 |
Why?
|
| Topotecan | 1 | 2011 | 132 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2020 | 2313 | 0.090 |
Why?
|
| Physician-Patient Relations | 5 | 2011 | 3242 | 0.090 |
Why?
|
| Telephone | 2 | 2014 | 624 | 0.090 |
Why?
|
| Radiation-Protective Agents | 2 | 2002 | 88 | 0.090 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2010 | 16 | 0.090 |
Why?
|
| Incidence | 9 | 2016 | 21392 | 0.090 |
Why?
|
| Antigens, Neoplasm | 2 | 2009 | 1998 | 0.090 |
Why?
|
| Prednisone | 4 | 2014 | 1565 | 0.090 |
Why?
|
| International Cooperation | 3 | 2012 | 1433 | 0.090 |
Why?
|
| Stroke Volume | 3 | 2016 | 5523 | 0.090 |
Why?
|
| Longitudinal Studies | 5 | 2014 | 14495 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 1152 | 0.090 |
Why?
|
| Inservice Training | 1 | 2013 | 375 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2016 | 975 | 0.090 |
Why?
|
| Benzothiazoles | 1 | 2011 | 246 | 0.090 |
Why?
|
| Expert Testimony | 3 | 2019 | 361 | 0.090 |
Why?
|
| Advisory Committees | 3 | 2009 | 788 | 0.090 |
Why?
|
| Cyclohexanols | 1 | 2010 | 126 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 529 | 0.090 |
Why?
|
| Sexual Behavior | 3 | 2012 | 2086 | 0.090 |
Why?
|
| Gene Amplification | 3 | 2010 | 1085 | 0.090 |
Why?
|
| Ovariectomy | 3 | 2014 | 611 | 0.090 |
Why?
|
| Protective Agents | 2 | 2002 | 150 | 0.090 |
Why?
|
| Piperidines | 2 | 2012 | 1650 | 0.090 |
Why?
|
| Megestrol Acetate | 2 | 2000 | 18 | 0.090 |
Why?
|
| Early Detection of Cancer | 6 | 2021 | 3202 | 0.090 |
Why?
|
| Data Collection | 6 | 2013 | 3315 | 0.080 |
Why?
|
| Telomere | 1 | 2016 | 933 | 0.080 |
Why?
|
| Genotype | 4 | 2019 | 12960 | 0.080 |
Why?
|
| Signal Transduction | 9 | 2021 | 23376 | 0.080 |
Why?
|
| Factor V | 1 | 2010 | 168 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2021 | 8313 | 0.080 |
Why?
|
| Intention to Treat Analysis | 2 | 2022 | 422 | 0.080 |
Why?
|
| Massachusetts | 3 | 2012 | 8803 | 0.080 |
Why?
|
| Body Composition | 3 | 2008 | 2419 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 685 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2021 | 3663 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 15789 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2016 | 3800 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 2532 | 0.080 |
Why?
|
| Drug Costs | 2 | 2015 | 1185 | 0.080 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2009 | 124 | 0.080 |
Why?
|
| Reference Values | 1 | 2016 | 4925 | 0.080 |
Why?
|
| Macrophages | 2 | 2021 | 5745 | 0.080 |
Why?
|
| Financing, Government | 2 | 2009 | 472 | 0.080 |
Why?
|
| Bone Density | 2 | 2012 | 3534 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2014 | 1343 | 0.080 |
Why?
|
| Health Status Disparities | 4 | 2015 | 1830 | 0.080 |
Why?
|
| Ambulatory Care | 3 | 2007 | 2781 | 0.080 |
Why?
|
| California | 1 | 2012 | 1416 | 0.080 |
Why?
|
| Selective Estrogen Receptor Modulators | 4 | 2010 | 132 | 0.080 |
Why?
|
| DNA Damage | 1 | 2018 | 2442 | 0.080 |
Why?
|
| Therapies, Investigational | 1 | 2008 | 112 | 0.070 |
Why?
|
| Feasibility Studies | 7 | 2019 | 5201 | 0.070 |
Why?
|
| Liver Neoplasms | 4 | 2018 | 4319 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2016 | 2506 | 0.070 |
Why?
|
| Hot Flashes | 1 | 2010 | 328 | 0.070 |
Why?
|
| Heterozygote | 5 | 2015 | 2798 | 0.070 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 260 | 0.070 |
Why?
|
| Primary Health Care | 4 | 2007 | 4647 | 0.070 |
Why?
|
| Urogenital Neoplasms | 1 | 2008 | 135 | 0.070 |
Why?
|
| Animals | 19 | 2022 | 167963 | 0.070 |
Why?
|
| Prevalence | 7 | 2020 | 15687 | 0.070 |
Why?
|
| Thrombocytopenia | 2 | 2014 | 1174 | 0.070 |
Why?
|
| Reality Therapy | 1 | 2006 | 5 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 2895 | 0.070 |
Why?
|
| Educational Status | 4 | 2012 | 2515 | 0.070 |
Why?
|
| Resistance Training | 1 | 2009 | 185 | 0.070 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2016 | 2128 | 0.070 |
Why?
|
| Waist-Hip Ratio | 1 | 2008 | 516 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 296 | 0.070 |
Why?
|
| Troponin I | 1 | 2011 | 638 | 0.070 |
Why?
|
| Prostheses and Implants | 1 | 1993 | 1273 | 0.070 |
Why?
|
| Benzimidazoles | 2 | 2021 | 858 | 0.070 |
Why?
|
| Lymphopenia | 1 | 2008 | 280 | 0.070 |
Why?
|
| Ventricular Function, Left | 3 | 2016 | 3880 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2020 | 36290 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2011 | 638 | 0.070 |
Why?
|
| Axons | 1 | 2014 | 1673 | 0.060 |
Why?
|
| Multifactorial Inheritance | 1 | 2014 | 1365 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2006 | 397 | 0.060 |
Why?
|
| Anthropometry | 1 | 2010 | 1348 | 0.060 |
Why?
|
| Ligands | 2 | 2022 | 3276 | 0.060 |
Why?
|
| Fertility Agents | 1 | 2005 | 11 | 0.060 |
Why?
|
| Leukemia | 2 | 2006 | 1520 | 0.060 |
Why?
|
| Preventive Medicine | 1 | 2007 | 250 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2006 | 377 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2021 | 724 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 410 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2021 | 2014 | 0.060 |
Why?
|
| Drug Utilization | 2 | 2002 | 1195 | 0.060 |
Why?
|
| Antiemetics | 1 | 2006 | 187 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2014 | 1977 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 2919 | 0.060 |
Why?
|
| Imidazoles | 1 | 2011 | 1180 | 0.060 |
Why?
|
| Daunorubicin | 1 | 2004 | 156 | 0.060 |
Why?
|
| Apoptosis | 2 | 2021 | 9501 | 0.060 |
Why?
|
| Radiopharmaceuticals | 3 | 2021 | 2634 | 0.060 |
Why?
|
| Stress, Psychological | 3 | 2012 | 4446 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 5130 | 0.060 |
Why?
|
| Social Class | 2 | 2010 | 2005 | 0.060 |
Why?
|
| Comprehension | 2 | 2007 | 618 | 0.060 |
Why?
|
| Lung Neoplasms | 6 | 2018 | 13262 | 0.060 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 5397 | 0.060 |
Why?
|
| Genome, Human | 4 | 2021 | 4417 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 8624 | 0.060 |
Why?
|
| Genetic Markers | 4 | 1999 | 2608 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2020 | 4642 | 0.060 |
Why?
|
| Depression | 5 | 2012 | 8044 | 0.060 |
Why?
|
| Sirolimus | 1 | 2011 | 1547 | 0.060 |
Why?
|
| Mitotic Index | 2 | 2017 | 161 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2009 | 707 | 0.060 |
Why?
|
| North Carolina | 2 | 2002 | 325 | 0.060 |
Why?
|
| Antigen Presentation | 2 | 2021 | 1254 | 0.060 |
Why?
|
| Social Adjustment | 1 | 2006 | 632 | 0.060 |
Why?
|
| Forecasting | 3 | 2008 | 2932 | 0.060 |
Why?
|
| Nurse-Patient Relations | 1 | 2004 | 100 | 0.060 |
Why?
|
| Hydroxyurea | 1 | 2005 | 282 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 1375 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2006 | 1796 | 0.060 |
Why?
|
| Models, Organizational | 1 | 2007 | 545 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2016 | 3047 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2005 | 345 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2010 | 1017 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2015 | 1943 | 0.060 |
Why?
|
| Unnecessary Procedures | 1 | 2007 | 413 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 796 | 0.050 |
Why?
|
| Genital Neoplasms, Female | 1 | 2008 | 533 | 0.050 |
Why?
|
| Xerostomia | 1 | 2003 | 94 | 0.050 |
Why?
|
| Cross-Over Studies | 3 | 2020 | 2061 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 5791 | 0.050 |
Why?
|
| Positron-Emission Tomography | 4 | 2017 | 6465 | 0.050 |
Why?
|
| Fever | 2 | 2011 | 1617 | 0.050 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 539 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2014 | 1153 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 4107 | 0.050 |
Why?
|
| Ovulation Induction | 1 | 2005 | 277 | 0.050 |
Why?
|
| Alopecia | 1 | 2007 | 414 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2003 | 86 | 0.050 |
Why?
|
| Mice | 10 | 2022 | 81208 | 0.050 |
Why?
|
| Health Care Costs | 2 | 2008 | 3258 | 0.050 |
Why?
|
| Constipation | 1 | 2007 | 561 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 3527 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2004 | 249 | 0.050 |
Why?
|
| Drug Therapy, Combination | 4 | 2016 | 6498 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 1178 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2007 | 717 | 0.050 |
Why?
|
| Parity | 2 | 2015 | 925 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2007 | 1724 | 0.050 |
Why?
|
| Health Services Research | 1 | 2009 | 1810 | 0.050 |
Why?
|
| Patient Rights | 1 | 2002 | 125 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2012 | 2520 | 0.050 |
Why?
|
| Demography | 1 | 2006 | 1650 | 0.050 |
Why?
|
| Vincristine | 3 | 2014 | 1039 | 0.050 |
Why?
|
| Drug Interactions | 2 | 2009 | 1428 | 0.050 |
Why?
|
| Analysis of Variance | 4 | 2020 | 6238 | 0.050 |
Why?
|
| Genomic Instability | 2 | 2016 | 704 | 0.050 |
Why?
|
| Insurance Coverage | 2 | 2010 | 1939 | 0.050 |
Why?
|
| Thiotepa | 1 | 2001 | 66 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 20509 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 786 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 74 | 0.050 |
Why?
|
| Leptin | 1 | 2009 | 1591 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2008 | 951 | 0.050 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2012 | 162 | 0.050 |
Why?
|
| Models, Biological | 3 | 2018 | 9467 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2006 | 814 | 0.050 |
Why?
|
| Premedication | 1 | 2021 | 253 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 566 | 0.050 |
Why?
|
| Progestins | 1 | 2003 | 302 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 1431 | 0.050 |
Why?
|
| Gadolinium | 1 | 2006 | 959 | 0.050 |
Why?
|
| Organizational Policy | 1 | 2003 | 429 | 0.050 |
Why?
|
| Chelating Agents | 1 | 2002 | 384 | 0.050 |
Why?
|
| Algorithms | 5 | 2012 | 13981 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2006 | 1388 | 0.040 |
Why?
|
| Drug Industry | 1 | 2007 | 789 | 0.040 |
Why?
|
| Genetic Counseling | 2 | 2002 | 624 | 0.040 |
Why?
|
| Hospice Care | 1 | 2007 | 692 | 0.040 |
Why?
|
| Social Support | 2 | 2008 | 2145 | 0.040 |
Why?
|
| Cross-Sectional Studies | 7 | 2013 | 25942 | 0.040 |
Why?
|
| Mammaplasty | 3 | 2013 | 1240 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2006 | 1403 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 9530 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 2 | 2007 | 755 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2009 | 2062 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2020 | 101 | 0.040 |
Why?
|
| Publishing | 1 | 2007 | 836 | 0.040 |
Why?
|
| Genome-Wide Association Study | 3 | 2015 | 12626 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2003 | 430 | 0.040 |
Why?
|
| Disease Management | 3 | 2015 | 2514 | 0.040 |
Why?
|
| Polyesters | 1 | 2001 | 372 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 1999 | 149 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2006 | 1927 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 981 | 0.040 |
Why?
|
| Drug Monitoring | 2 | 2019 | 965 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2001 | 410 | 0.040 |
Why?
|
| Fractures, Bone | 1 | 2011 | 2041 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2005 | 650 | 0.040 |
Why?
|
| Hematologic Diseases | 2 | 2001 | 496 | 0.040 |
Why?
|
| Heart Failure | 4 | 2013 | 11847 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 3839 | 0.040 |
Why?
|
| Early Diagnosis | 2 | 2017 | 1180 | 0.040 |
Why?
|
| Staurosporine | 1 | 2020 | 242 | 0.040 |
Why?
|
| Proteomics | 3 | 2020 | 3817 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 698 | 0.040 |
Why?
|
| Calcinosis | 1 | 2007 | 1476 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 1998 | 4625 | 0.040 |
Why?
|
| Blood Donors | 1 | 2020 | 343 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2021 | 695 | 0.040 |
Why?
|
| Affect | 1 | 2006 | 1480 | 0.040 |
Why?
|
| Aminoglycosides | 1 | 1999 | 163 | 0.040 |
Why?
|
| Thiophenes | 1 | 2003 | 587 | 0.040 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 20080 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2021 | 374 | 0.040 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 1019 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2020 | 319 | 0.040 |
Why?
|
| DNA-Binding Proteins | 3 | 2012 | 9585 | 0.040 |
Why?
|
| Mind-Body Therapies | 1 | 2021 | 265 | 0.040 |
Why?
|
| Hematinics | 1 | 2001 | 281 | 0.040 |
Why?
|
| Pain | 4 | 2011 | 5066 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2005 | 1725 | 0.040 |
Why?
|
| Cognition Disorders | 2 | 2004 | 3976 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2003 | 570 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2013 | 326 | 0.040 |
Why?
|
| Hypesthesia | 1 | 1998 | 107 | 0.040 |
Why?
|
| Energy Metabolism | 2 | 2001 | 2869 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 226 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2006 | 2773 | 0.040 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 5325 | 0.040 |
Why?
|
| Osteoporosis | 2 | 2014 | 1600 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2007 | 916 | 0.040 |
Why?
|
| Melphalan | 2 | 1999 | 420 | 0.040 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1998 | 116 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2011 | 2435 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2014 | 2932 | 0.040 |
Why?
|
| Sarcoma | 1 | 2008 | 1786 | 0.040 |
Why?
|
| Rats, Inbred Strains | 2 | 1995 | 2094 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2018 | 246 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 206 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 1547 | 0.040 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 1677 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 4550 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 1628 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2016 | 64 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2018 | 347 | 0.030 |
Why?
|
| Capsules | 2 | 2013 | 192 | 0.030 |
Why?
|
| Sexuality | 1 | 1998 | 170 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2008 | 1895 | 0.030 |
Why?
|
| Mediator Complex Subunit 1 | 1 | 2016 | 30 | 0.030 |
Why?
|
| Boston | 2 | 2007 | 9280 | 0.030 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2016 | 86 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2006 | 3215 | 0.030 |
Why?
|
| Cell Count | 1 | 2020 | 1835 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2013 | 15697 | 0.030 |
Why?
|
| RNA, Double-Stranded | 1 | 2017 | 295 | 0.030 |
Why?
|
| Knowledge | 1 | 1997 | 176 | 0.030 |
Why?
|
| Life Tables | 1 | 1996 | 365 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 14660 | 0.030 |
Why?
|
| Receptors, Angiotensin | 1 | 1995 | 141 | 0.030 |
Why?
|
| Phosphoserine | 1 | 2016 | 203 | 0.030 |
Why?
|
| Genes, p53 | 2 | 2010 | 713 | 0.030 |
Why?
|
| Cognition | 1 | 2013 | 6957 | 0.030 |
Why?
|
| ROC Curve | 1 | 2003 | 3568 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 2016 | 122 | 0.030 |
Why?
|
| Drug Approval | 1 | 2022 | 816 | 0.030 |
Why?
|
| Body Temperature Regulation | 1 | 1997 | 286 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2019 | 2262 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1996 | 157 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2005 | 1940 | 0.030 |
Why?
|
| Hypertension | 2 | 2014 | 8594 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2015 | 49 | 0.030 |
Why?
|
| Craniotomy | 1 | 2019 | 741 | 0.030 |
Why?
|
| Thalidomide | 1 | 2000 | 884 | 0.030 |
Why?
|
| Models, Animal | 1 | 2001 | 2117 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 1995 | 4291 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 3387 | 0.030 |
Why?
|
| Heart | 1 | 2008 | 4393 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2000 | 759 | 0.030 |
Why?
|
| Sick Role | 2 | 2008 | 230 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2016 | 1142 | 0.030 |
Why?
|
| Jews | 1 | 2016 | 364 | 0.030 |
Why?
|
| Integrin alpha4 | 1 | 2014 | 87 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1998 | 1055 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 731 | 0.030 |
Why?
|
| Protein Phosphatase 2 | 1 | 2016 | 236 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2015 | 171 | 0.030 |
Why?
|
| Interferons | 1 | 2017 | 705 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 18137 | 0.030 |
Why?
|
| RNA Interference | 1 | 2022 | 2846 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6131 | 0.030 |
Why?
|
| Employment | 2 | 2005 | 1112 | 0.030 |
Why?
|
| Viruses | 1 | 2017 | 376 | 0.030 |
Why?
|
| Energy Intake | 2 | 2001 | 2129 | 0.030 |
Why?
|
| Health Status | 2 | 2005 | 4081 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2008 | 6381 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2005 | 3185 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 2009 | 1440 | 0.030 |
Why?
|
| Depressive Disorder | 2 | 2012 | 3726 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 1999 | 867 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2016 | 421 | 0.030 |
Why?
|
| Receptor, EphA5 | 1 | 2012 | 10 | 0.030 |
Why?
|
| Tablets | 1 | 2013 | 149 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 2802 | 0.030 |
Why?
|
| Medical Records | 1 | 1998 | 1407 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2001 | 2417 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 507 | 0.030 |
Why?
|
| Case-Control Studies | 4 | 2016 | 22053 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 869 | 0.030 |
Why?
|
| Angiotensin II | 1 | 1995 | 849 | 0.030 |
Why?
|
| Income | 1 | 2021 | 1875 | 0.030 |
Why?
|
| Area Under Curve | 1 | 1997 | 1636 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 1347 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 2722 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 944 | 0.030 |
Why?
|
| Receptor, erbB-3 | 1 | 2013 | 143 | 0.030 |
Why?
|
| Postoperative Care | 1 | 1999 | 1479 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 640 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 2012 | 129 | 0.030 |
Why?
|
| Breast Implants | 1 | 1996 | 410 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1728 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 12965 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 555 | 0.020 |
Why?
|
| Comprehensive Health Care | 1 | 2013 | 124 | 0.020 |
Why?
|
| Age Distribution | 1 | 2018 | 2893 | 0.020 |
Why?
|
| Streptozocin | 1 | 1992 | 194 | 0.020 |
Why?
|
| Health Behavior | 2 | 2008 | 2622 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 653 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 1039 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2015 | 335 | 0.020 |
Why?
|
| Cardiovascular Diseases | 3 | 2004 | 15757 | 0.020 |
Why?
|
| Cooperative Behavior | 2 | 2010 | 1500 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 691 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 1999 | 1803 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 1837 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 1764 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 1296 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2021 | 3442 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2016 | 2627 | 0.020 |
Why?
|
| Pregnancy | 2 | 2015 | 29749 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2021 | 4090 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 384 | 0.020 |
Why?
|
| Nomograms | 1 | 2012 | 238 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 1889 | 0.020 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 15840 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2014 | 646 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2006 | 3562 | 0.020 |
Why?
|
| Micro-Electrical-Mechanical Systems | 1 | 2010 | 31 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 4169 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 11891 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 2007 | 641 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5649 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 666 | 0.020 |
Why?
|
| Cardiac Electrophysiology | 1 | 2009 | 59 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2016 | 1548 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2016 | 3607 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 165 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 1745 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2018 | 4264 | 0.020 |
Why?
|
| Age of Onset | 1 | 2016 | 3301 | 0.020 |
Why?
|
| Economics | 1 | 2010 | 141 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 2825 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 1952 | 0.020 |
Why?
|
| Methyltransferases | 1 | 1992 | 374 | 0.020 |
Why?
|
| Pedigree | 1 | 1997 | 4578 | 0.020 |
Why?
|
| Stroke | 1 | 2011 | 9962 | 0.020 |
Why?
|
| Rats | 4 | 1998 | 23711 | 0.020 |
Why?
|
| Climacteric | 1 | 2008 | 57 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2006 | 2897 | 0.020 |
Why?
|
| Developing Countries | 1 | 2021 | 2868 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 1997 | 2326 | 0.020 |
Why?
|
| Case Management | 1 | 2010 | 272 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3016 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2006 | 4555 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2698 | 0.020 |
Why?
|
| Marital Status | 1 | 2010 | 433 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 693 | 0.020 |
Why?
|
| Health Surveys | 2 | 2013 | 4063 | 0.020 |
Why?
|
| Smoking | 2 | 2010 | 9073 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 1998 | 1416 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2012 | 643 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3736 | 0.020 |
Why?
|
| Antineoplastic Protocols | 1 | 2007 | 50 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 1313 | 0.020 |
Why?
|
| Child | 2 | 2008 | 79806 | 0.020 |
Why?
|
| Liver | 1 | 2003 | 7509 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2014 | 3094 | 0.020 |
Why?
|
| Polyglutamic Acid | 1 | 2007 | 44 | 0.020 |
Why?
|
| Motivation | 1 | 1997 | 1993 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2440 | 0.020 |
Why?
|
| Governing Board | 1 | 2007 | 50 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1705 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2007 | 351 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 1135 | 0.020 |
Why?
|
| Consent Forms | 1 | 2007 | 55 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 2186 | 0.020 |
Why?
|
| Escape Reaction | 1 | 2006 | 57 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 3 | 2007 | 5508 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 926 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2000 | 11345 | 0.020 |
Why?
|
| Arousal | 1 | 2012 | 1157 | 0.020 |
Why?
|
| Cytokines | 1 | 2021 | 7343 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 1869 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 1218 | 0.020 |
Why?
|
| Freezing | 1 | 2007 | 306 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2007 | 301 | 0.020 |
Why?
|
| Fear | 1 | 2015 | 1462 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2008 | 1060 | 0.020 |
Why?
|
| Computational Biology | 1 | 2018 | 3505 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2015 | 1380 | 0.020 |
Why?
|
| Tocopherols | 1 | 2005 | 44 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 1668 | 0.020 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2006 | 147 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2013 | 3164 | 0.020 |
Why?
|
| Cytogenetics | 1 | 2006 | 198 | 0.020 |
Why?
|
| Hospitalization | 2 | 2021 | 10790 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 6853 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 1913 | 0.020 |
Why?
|
| Crosses, Genetic | 2 | 1998 | 751 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 5797 | 0.020 |
Why?
|
| Teaching Materials | 1 | 2005 | 84 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 4122 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 7593 | 0.020 |
Why?
|
| Medicaid | 2 | 2012 | 2815 | 0.020 |
Why?
|
| Guideline Adherence | 2 | 2007 | 2283 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 5496 | 0.020 |
Why?
|
| Radiation Pneumonitis | 1 | 2005 | 102 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 15620 | 0.010 |
Why?
|
| Linear Models | 2 | 2010 | 5877 | 0.010 |
Why?
|
| Canada | 1 | 2010 | 2128 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2012 | 2101 | 0.010 |
Why?
|
| Cause of Death | 1 | 2015 | 3725 | 0.010 |
Why?
|
| Confusion | 1 | 2006 | 279 | 0.010 |
Why?
|
| Authorship | 1 | 2007 | 281 | 0.010 |
Why?
|
| Spirituality | 1 | 2008 | 428 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2601 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 3075 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4541 | 0.010 |
Why?
|
| Models, Statistical | 2 | 2010 | 5075 | 0.010 |
Why?
|
| Protein Binding | 1 | 2016 | 9335 | 0.010 |
Why?
|
| Toremifene | 1 | 2003 | 24 | 0.010 |
Why?
|
| Adiponectin | 1 | 2009 | 1115 | 0.010 |
Why?
|
| Brain | 2 | 2020 | 26951 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2016 | 4938 | 0.010 |
Why?
|
| Genetic Loci | 1 | 2012 | 2618 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2006 | 510 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2007 | 632 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2010 | 2659 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1990 | 1378 | 0.010 |
Why?
|
| Office Visits | 1 | 2007 | 597 | 0.010 |
Why?
|
| New Jersey | 1 | 2003 | 291 | 0.010 |
Why?
|
| Carotenoids | 1 | 2005 | 620 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4573 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 4742 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2005 | 727 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 3758 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 6015 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2013 | 2963 | 0.010 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2002 | 42 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 2569 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2008 | 935 | 0.010 |
Why?
|
| Epoetin Alfa | 1 | 2001 | 79 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2003 | 426 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2015 | 12766 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 1376 | 0.010 |
Why?
|
| Southeastern United States | 1 | 2000 | 90 | 0.010 |
Why?
|
| Endometrium | 1 | 2003 | 403 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2015 | 14372 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2015 | 6551 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2003 | 403 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 7021 | 0.010 |
Why?
|
| Aging | 1 | 1999 | 8651 | 0.010 |
Why?
|
| Health Services | 1 | 2005 | 753 | 0.010 |
Why?
|
| Infection Control | 1 | 2007 | 983 | 0.010 |
Why?
|
| Trimetrexate | 1 | 1999 | 15 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 680 | 0.010 |
Why?
|
| Imides | 1 | 1999 | 15 | 0.010 |
Why?
|
| Naphthalimides | 1 | 1999 | 22 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2852 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2005 | 1677 | 0.010 |
Why?
|
| Cardiology | 1 | 2010 | 1723 | 0.010 |
Why?
|
| Diet | 1 | 1997 | 8010 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2005 | 1139 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 748 | 0.010 |
Why?
|
| Cost Savings | 1 | 2004 | 920 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 5785 | 0.010 |
Why?
|
| Decision Trees | 1 | 2000 | 506 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 1673 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2000 | 590 | 0.010 |
Why?
|
| Growth Substances | 1 | 2000 | 768 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 42063 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 673 | 0.010 |
Why?
|
| Empirical Research | 1 | 1998 | 120 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2000 | 392 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1804 | 0.010 |
Why?
|
| Leadership | 1 | 2007 | 1371 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 1399 | 0.010 |
Why?
|
| Isoquinolines | 1 | 1999 | 353 | 0.010 |
Why?
|
| Lymphokines | 1 | 2000 | 927 | 0.010 |
Why?
|
| Health Policy | 1 | 2009 | 2677 | 0.010 |
Why?
|
| Genetic Research | 1 | 1998 | 172 | 0.010 |
Why?
|
| Risk Management | 1 | 2000 | 558 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4166 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 1628 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2010 | 2758 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1992 | 1617 | 0.010 |
Why?
|
| Women | 1 | 1998 | 225 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2006 | 2912 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 2176 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 1995 | 151 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 1995 | 186 | 0.010 |
Why?
|
| Genomic Library | 1 | 1995 | 189 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 5870 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2010 | 4373 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1995 | 422 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2001 | 1521 | 0.010 |
Why?
|
| Absorption | 1 | 1994 | 243 | 0.010 |
Why?
|
| Base Sequence | 2 | 1995 | 12446 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2007 | 5961 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2001 | 1328 | 0.010 |
Why?
|
| Biological Availability | 1 | 1994 | 395 | 0.010 |
Why?
|
| Adenine | 1 | 1999 | 975 | 0.010 |
Why?
|
| Half-Life | 1 | 1994 | 652 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 2882 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 1385 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1995 | 786 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2006 | 3340 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 17624 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 5305 | 0.010 |
Why?
|
| Software | 1 | 2006 | 4419 | 0.010 |
Why?
|
| X Chromosome | 1 | 1995 | 815 | 0.010 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 1992 | 83 | 0.010 |
Why?
|
| Counseling | 1 | 2000 | 1548 | 0.010 |
Why?
|
| Genes | 1 | 1995 | 1845 | 0.010 |
Why?
|
| Species Specificity | 1 | 1995 | 2418 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 2819 | 0.010 |
Why?
|
| Genome | 1 | 1998 | 1739 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1992 | 865 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 4357 | 0.000 |
Why?
|
| Electrocardiography | 1 | 2002 | 6414 | 0.000 |
Why?
|
| Caregivers | 1 | 2000 | 2224 | 0.000 |
Why?
|
| Random Allocation | 1 | 1990 | 2394 | 0.000 |
Why?
|
| Dietary Fats | 1 | 1993 | 1992 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 8158 | 0.000 |
Why?
|
| Private Practice | 1 | 1985 | 152 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1992 | 2611 | 0.000 |
Why?
|
| Membrane Glycoproteins | 1 | 1992 | 3707 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 7408 | 0.000 |
Why?
|